Kozanczyn Christa, Collins Katie, Fernandez Conrad V
School of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Account Res. 2007 Oct-Dec;14(4):255-67. doi: 10.1080/08989620701670179.
This study aims to determine the nature of United States Institutional Review Board (IRB) policy in a broad spectrum of research settings regarding the return of results to study participants.
IRB policies or standard operating procedures of 207 Medical School, Industry and Non-medical School IRBs were examined on-line to determine if they incorporated specific reference to the return of results to participants at the conclusion of the research.
The majority of IRBs had no available policy regarding the return of research results to participants [56% (n = 116)]. A further third 136.3% (n = 75)] had policies that were defined as vague or that only indirectly mentioned the return of results. Medical School IRBs were more likely to have a policy than Industry or Non-medical University IRBs, respectively (odds ratio, 4.63; 95% confidence interval, 1.84 to 11.66 and odds ratio, 3.03; 95 % confidence interval, 1.75 to 5.25). Few provided any guidance as to the process of return of results. Of the IRBs that had a research results policy, 54.9% (n = 50) specifically addressed genetic research.
Our findings demonstrate a marked lack of uniformity in IRB policy regarding the return of study results with over half providing no guidance.
本研究旨在确定美国机构审查委员会(IRB)在广泛研究环境中关于向研究参与者反馈研究结果的政策性质。
对207个医学院、企业和非医学院IRB的IRB政策或标准操作程序进行在线审查,以确定它们是否在研究结束时纳入了向参与者反馈结果的具体内容。
大多数IRB没有关于向参与者反馈研究结果的可用政策[56%(n = 116)]。另有三分之一[36.3%(n = 75)]的政策被定义为模糊或仅间接提及结果反馈。医学院的IRB比企业或非医科大学的IRB更有可能制定相关政策(优势比分别为4.63;95%置信区间为1.84至11.66和优势比为3.03;95%置信区间为1.75至5.25)。很少有IRB对结果反馈过程提供任何指导。在有研究结果政策的IRB中,54.9%(n = 50)专门涉及基因研究。
我们的研究结果表明,IRB在研究结果反馈政策方面明显缺乏一致性,超过一半的IRB未提供任何指导。